Abstract:Background: The BRAF V600E mutation in colorectal cancer (CRC) is a significant indicator of poor prognosis, especially in tumors exhibiting microsatellite instability (MSI). It is more common on the right side of the colon but can occur anywhere within the colon. Although other BRAF mutations existed, current research primarily focused on BRAF V600E. Most clinical data sets were centered on advanced colorectal cancer. There was limited understanding of the molecular characteristics of early-stage colorectal cancer patients with BRAF mutations, which impacted postoperative prognosis management, including refining adjuvant therapy regimens. Therefore, we analyzed the molecular characteristics of early-stage CRC surgical patients. Methods: Tumor tissue from 767 early-stage CRC patients diagnosed between 2021 to 2022 in China were analyzed using NGS (panel on 733 gene) to validate the mutation characteristics. Tumor specimens were tested for the BRAF mutation and MSI status. Result: Among 767 early CRC cases tested, BRAF mutations accounted for 6.52% (50/767), with 62% (31/50) being BRAF V600E, followed by 14% (7/50) for BRAF D594G. Notably, there were two cases of fusion variations, TRIM24-BRAF, and one case of BRAF copy gain. Among the BRAF mutation population, 11 cases were MSI-H, with 8 of them being BRAF V600E/MSI-H. Only one MSH-H patient had a germline mutation in the MLH1 gene, with a concurrent mutation in BRAF K601T.Interestingly, when comparing the mutation profiles of the BRAF V600E population with those of the non-V600E BRAF mutation population, we found distinct co-mutated genes despite both being BRAF mutations. In the BRAF V600E group, the top three frequently mutated genes were TP53 (52%), RNF43 (32%), and SMAD4 (32%). Additionally, the BRAF V600E/MSI-H subgroup presented a distinct mutation profile, with minimal occurrences of TP53 and SMAD4 mutations. In the non-V600E BRAF mutation group, the top three frequently mutated genes were TP53 (84%), APC (63%), and KRAS (32%). Conclusions: In examining the mutation profile characteristics of early colorectal cancer with BRAF mutations, the proportion of BRAF V600E/MSI-H appeared to have been lower than that reported in advanced cases. Furthermore, in terms of the frequency of co-mutated genes, it seemed that BRAF V600E had exhibited a higher malignant driving mutation effect as a single gene, while non-V600E mutations had required more cooperative tumor suppressor genes or oncogenes. Analyzing the molecular characteristics of early colorectal cancer patients with V600E and non-V600E BRAF mutations could help improve postoperative management and further our understanding of tumor progression. Citation Format: Zhang Quan An. Molecular characteristic profile in early colorectal cancer with V600E and non-V600E BRAF mutations [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 2566.

BRAF Mutation As a Potential Marker to Identify the Proximal Colon Serrated Polyps with Malignant Potential.

BRAF V600E Mutation and the Bethesda System for Reporting Thyroid Cytopathology of Fine-Needle Aspiration Biopsy for Distinguishing Benign from Malignant Thyroid Nodules

BRAF V600E mutation detection by immunohistochemistry in colorectal carcinoma

Detection Of Kras Gene Mutations In Endoscopic Ultrasound-Guided Fine-Needle Aspiration Biopsy For Improving Pancreatic Cancer Diagnosis

Clinicopathologic Distribution of KRAS and BRAF Mutations in a Chinese Population with Colorectal Cancer Precursor Lesions

Diagnostic Value of BRAF (V600e)-Mutation Analysis in Fine-Needle Aspiration of Thyroid Nodules: a Meta-Analysis.

IDDF2020-ABS-0070 Proteomic Analysis of Colorectal Cancer with BRAFV600E Mutation

A clinicopathological and molecular analysis of 200 traditional serrated adenomas

Specific Immunohistochemical Detection of the BRAF V600E Mutation in Primary and Metastatic Papillary Thyroid Carcinoma.

Immunohistochemistry with a mutation-specific monoclonal antibody as a screening tool for the BRAFV600E mutational status in primary cutaneous malignant melanoma

Clinical Significance of BRAFV600E Mutation in Circulating Tumor DNA in Chinese Patients with Melanoma

Abstract 2566: Molecular characteristic profile in early colorectal cancer with V600E and non-V600E BRAF mutations

Clinicopathological features of BRAF V600E mutated gastrointestinal stromal tumors

[Application of BRAF V600E Mutation-Specific Immunohistochemistry in Diagnosis of Gastrointestinal Stromal Tumors].

Molecular pathological epidemiology of colorectal cancer in Chinese patients with KRAS and BRAF mutations

Clinical Research Progress on BRAF V600E-mutant Advanced Colorectal Cancer.

Externalization of saw-tooth architecture in small serrated polyps implies the presence of methylation of IGFBP7

Immunohistochemical Detection of the BRAF V600E Mutation in Melanoma Patients with Monoclonal Antibody VE1

A further investigation of combined mismatch repair and BRAFV600E mutation specific immunohistochemistry as a predictor of overall survival in colorectal carcinoma

BRAF Mutation as a Potential Therapeutic Target for Checkpoint Inhibitors: A Comprehensive Analysis of Immune Microenvironment in BRAF Mutated Colon Cancer

Clinicopathologic Features and Treatment Efficacy of Chinese Patients with BRAF -Mutated Metastatic Colorectal Cancer: a Retrospective Observational Study